Despite the crucial clinical benefits of CDK4/6 inhibitors in HR+ breast cancer [18], studies have shown that approximately 20% of patients with HR+ breast cancer develop primary resistance to CDK4/6 inhibitors [19], and more than 30% experience secondary resistance [20]. This evidence concerns the gene CDK4 and breast cancer.